SUTRO BIOPHARMA, INC.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
STRO$10.61+10.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $58,130 | $190,304 |
| Marketable securities | 83,298 | 126,591 |
| Accounts receivable | 3,977 | 8,616 |
| Prepaid expenses and other current assets | 5,521 | 17,799 |
| Total current assets | 150,926 | 343,310 |
| Property and equipment, net | 10,648 | 18,190 |
| Operating lease right-of-use assets | 10,903 | 17,677 |
| Other non-current assets | 495 | 7,172 |
| Restricted cash | 858 | 858 |
| Total assets | $173,830 | $387,207 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $7,565 | $10,475 |
| Accrued compensation | 14,642 | 12,905 |
| Deferred revenue-current | 10,562 | 69,783 |
| Operating lease liability-current | 7,783 | 7,480 |
| Accrued expenses and other current liabilities | 34,581 | 31,250 |
| Total current liabilities | 75,133 | 131,893 |
| Deferred revenue, non-current | 2,028 | 12,536 |
| Operating lease liability-non-current | 7,891 | 15,674 |
| Deferred royalty obligation related to the sale of future royalties | 219,536 | 180,809 |
| Other non-current liabilities | 1,694 | 1,694 |
| Total liabilities | 306,282 | 342,606 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value — 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 8,584,309 and 8,306,398 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 9 | 8 |
| Additional paid-in-capital | 845,475 | 831,423 |
| Accumulated other comprehensive income | 19 | 39 |
| Accumulated deficit | (977,955) | (786,869) |
| Total stockholders’ equity (deficit) | (132,452) | 44,601 |
| Total Liabilities and Stockholders’ Equity (Deficit) | $173,830 | $387,207 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.